Monday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial.  The trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab) compared to Keytruda alone as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV).  Also Read: Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook. Data from a pre-planned analysis showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria.  A higher discontinuation rate ...